Ginkgolide B liposome medicinal composition

A ginkgolide and liposome technology, which is applied in the directions of liposome delivery, drug combination, and devices that make drugs into special physical or taking forms, etc., can solve the problem of increasing leakage rate, large changes, organic solvent residues, etc. problem, to achieve the effect of improving the therapeutic index

Inactive Publication Date: 2010-12-15
刘会梅
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

High-pressure homogenization method and ultrasonic method can control the particle size, but high-energy crushing will damage the raw material medicine; the latter four methods cannot control the particle size, and the particle size distribution is not concentrated, organic solvent residues, leakage, precipitation, coagulation, Quality problems such as phospholipid corruption;
[0006] 3. The existing liposome preparation method makes the encapsulation efficiency of the liposome-combined drug carrier not reach 100%, and each batch fluctuates and changes greatly; the leakage rate is large, and the significance of the liposome-combined drug is lost;
[0007] 4. The production process is troublesome, energy-consuming and time-consuming, equipment investment is large, the prescription and process are not reliable and immature, resulting in uncontrollable, unstable and poor reproducibility of the preparation quality;
[0008] 5. Improper methods of sterilization and depyrogenation, it is difficult to guarantee

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ginkgolide B liposome medicinal composition
  • Ginkgolide B liposome medicinal composition
  • Ginkgolide B liposome medicinal composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0057] The raw material drug is a liposome combination drug with strong fat solubility. The molar ratio of each raw material component of the standard is as follows:

[0058] 1. The raw materials are alprostadil and indapamide

[0059] Mole number 1:30 composition 0.03

[0060] 2. Phospholipid raw materials are hydrogenated soybean lecithin and egg yolk lecithin

[0061] 2.5:1 molar composition 0.45

[0062] 3. The antioxidant is a combination of reduced glutathione and vitamin C with a molar ratio of 1:1 0.01

[0063] 4. The molecular diluent of phospholipid membrane is dimercaprol 0.90

[0064] 5. Liposome drug-loaded dispersant and excipient

[0065] It is a composition of xylitol and sodium glutamate molar ratio 5:1 0.90

[0066] 6. Surfactant is sodium dehydrocholate 0.01

[0067] 7. Ethanol 90% (v / v) (when dry, evaporate to the fullest) appropriate amount

[0068] 8. Phosphate buffer solution for injection 0.01M pH value 5.0-8.0 appropriate amount

[0069] 9. Wat...

Embodiment 2

[0072] The raw material drug is a liposome combination drug with strong fat solubility. The molar ratio of each raw material component of the standard is as follows:

[0073] 1. The raw materials are alprostadil and indapamide

[0074] Mole number 1:30 composition 0.10

[0075] 2. Phospholipid raw materials are hydrogenated soybean lecithin and egg yolk lecithin

[0076] Molar ratio 2.5:1 composition 1.20

[0077] 3. The antioxidant is a combination of reduced glutathione and vitamin C with a molar ratio of 1:1 0.07

[0078] 4. The molecular diluent of phospholipid membrane is dimercaprol 1.50

[0079] 5. The liposome drug-loaded dispersant and excipients are xylitol and sodium glutamate

[0080] Molar ratio 5:1 composition 3.00

[0081] 6. Surfactant is sodium dehydrocholate 0.07

[0082] 7. Ethanol 90% (v / v) (when dry, evaporate to the fullest) appropriate amount

[0083] 8. Phosphate buffer for injection 0.03M pH 5.0-8.0 appropriate amount

[0084] 9. Water for Inje...

Embodiment 3

[0087] The raw material drug is a liposome combination drug with strong fat solubility. The molar ratio of each raw material component of the standard is as follows:

[0088] 1. The raw materials are alprostadil and indapamide

[0089] Mole number 1:30 composition 0.03

[0090] 2. Phospholipid raw materials are hydrogenated soybean lecithin and egg yolk lecithin

[0091] Molar ratio 2.5:1 composition 1.20

[0092] 3. The antioxidant is a combination of reduced glutathione and vitamin C with a molar ratio of 1:1 0.01

[0093] 4. The molecular diluent of phospholipid membrane is dimercaprol 1.50

[0094] 5. Liposome drug-loaded dispersant and excipient

[0095] It is a composition of xylitol and sodium glutamate molar ratio 5:1 0.90

[0096] 6. Surfactant is sodium dehydrocholate 0.037

[0097] 7. Ethanol 95% (v / v) (when dry, evaporate to the fullest) appropriate amount

[0098] 8. Phosphate buffer solution for injection 0.02M pH value 5.0-8.0 appropriate amount

[0099]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention aims to industrially produce ginkgolide B liposome medicinal composition injection and ginkgolide B liposome medicinal composition oral preparations through uniform formula, process and equipment by a molecule dispersing method. The invention provides a molar ratio formula of the component raw materials for preparing the ginkgolide B liposome medicinal composition, steps and method for preparing ginkgolide B liposome medicinal composition freeze-dried injection and oral preparations, and embodiments for preparation. The ginkgolide B liposome medicinal composition is used for treating cerebral and vascular diseases.

Description

[0001] This application is an application enjoying domestic priority. The country of the earlier application is China, the application number of the earlier application is 201010248597.3, the application date is August 9, 2010, and the name is "Large-scale Industrial Production of Liposome Combination Drugs by Molecular Dispersion Method". technical field [0002] The invention relates to a method for preparing a liposome combination medicine in large-scale industrial production. Production of oral formulations of liposomal combination drugs. Background technique [0003] The gap between my country's pharmaceutical technology and raw material drug preparation technology and the international advanced level is only within 5 years, and some have reached or exceeded the international advanced level, and the preparation technology is 10-20 years behind the international advanced level. At present, a large number of second-generation common preparations are produced, while third...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/127A61K47/26A61K47/20A61K47/18A61K47/24A61K31/365A61J3/00A61P9/00A61K47/22
Inventor 刘会梅张连印蔡海德
Owner 刘会梅
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap